Article PDF :

Veiw Full Text PDF

Volume :

4

Issue :

4

Abstract :

The objective of the research work was to design and evaluate an in situ implant system of an anti-inflammatory drug. Deflazacort was the selected drug for the study. In situ formation of the implant was achieved by temperatere trigger approach. Combination of poloxamer 188 and poloxamer 407 was the selected thermoresponsive polymers. Optimization of the formulations was done based on gelation temperature, gel melting temperature, gelling time, gel duration, % entrapment efficiency etc. The optimized batch of FTH-2 exhibited a gelation temperature of 34.6 ± 0.26°C, gel melting temperature of 52.1 ± 0.25°C, gelling time of 5.4 ± 0.02 sec, and gel duration 172 ± 2.1, % entrapment efficiency of 78.4%. Based on these results it was decided that Insitu formulations with a Concentration of thermoreversible polymers, poloxamer 188 at 10% and poloxamer 407 at 17%. The burst release was controlled with incorporation of rate controlling polymer HPMC K4M at 1%. The process parameters was subjected to optimization and the results revealed that at mixing RPM of 2000, mixing time of 24 hrs resulted in formulation with ideal characteristics. The in vitro release of Deflazacort from the optimized batch, FTH-2 showed a controlled burst release of 06.39 ± 0.29 in initial 6 hours and 14.57 ± 0.14% on day-1 and the release was extended up to 168 hour (7days). The drug release of this batch when subjected to pharmacokinetics studies using various models showed that the data best into zero order and Higuchi release kinetic model with a coefficient of determination (R2 ) value of 0.9989 and 0.9330. Linearity to Higuchi kinetic model indicated a diffusion controlled drug release. The release component (n) from peppas model was found to be 0.87, which indicated non-fickian diffusion from which it can be assumed that the drug delivery system under study is a swellable device and drug release followed an erosion controlled mechanism.